Hofseth BioCare ASA Successfully Completes a Private Placement
Hofseth BioCare ASA, often referred to as HBC, has recently completed a significant private placement aimed at enhancing its growth capital and strengthening its corporate balance sheet. This strategic move is set to fund the company's ongoing developments and initiatives effectively.
The Details of the Private Placement
In an announcement concerning the private placement, the company disclosed that between 86,096,132 and 100,638,889 new shares, known as Offer Shares, were made available at a fixed price of NOK 1.80 per share. Ultimately, 87,811,110 Offer Shares were allocated at this price, bringing in gross proceeds of approximately NOK 158 million. The funds from this placement will primarily be utilized for growth, improving the balance sheet, and general corporate purposes which is crucial for a company operating in the competitive bio-agricultural sector.
Investment Commitments from Key Investors
The private placement saw substantial pre-commitments from notable investors. Among them, Guy Urquhart secured a significant share of 55,444,444 Offer Shares, amounting to roughly NOK 100 million. Additionally, GCI Hofseth LLC and Hofseth International AS were allocated 2,000,000 and 28,666,666 Offer Shares respectively, which highlights the investor confidence in Hofseth BioCare’s strategic direction.
Settlement in Two Tranches
The settlement of the private placement will occur in two distinct tranches. The first tranche aims to raise NOK 106.5 million through the issuance of shares authorized at the annual general meeting held in May. The second tranche, expected to issue shares worth NOK 28,666,666, will be dependent on the resolutions passed at an extraordinary general meeting slated for later this year. The company’s move to settle in tranches reflects a prudent approach to managing investor expectations and regulatory obligations.
Future Outlook Following the Placement
Upon completion of the private placement, Hofseth BioCare is projected to have a substantial share capital of NOK 48,289,214.40 divided among approximately 482,892,140 ordinary shares and additional preference shares held by its major shareholders. This financial structuring not only strengthens HBC's market position but also upholds compliance with Norway's financial regulations.
Subsequent Offerings for Additional Growth
In a further effort to ensure inclusivity among existing shareholders, HBC has proposed a subsequent offering of shares. This initiative is designed to offer up to 16,666,666 new shares, echoing their commitment to raising additional capital while adhering to market valuations favorable to shareholders. The subscription price will mirror that of the private placement, offering a judicious option for investors.
Corporate Governance and Investor Relations
The board's decision-making demonstrates a keen awareness of investor sentiments and regulatory parameters. By prioritizing shareholder engagement and maintaining transparency regarding the private placement process, Hofseth BioCare illustrates its dedication to fostering strong relations with its investors, which is foundational for sustaining long-term growth.
For anyone seeking further information or inquiries, Jon Olav Ødegård, the CEO of HBC, is approachable via phone or email, showcasing the company’s accessibility and commitment to open communication.
Frequently Asked Questions
What was the purpose of the private placement by Hofseth BioCare?
The private placement aimed to secure growth capital, strengthen the balance sheet, and provide funds for general corporate purposes.
How many shares were allocated in the private placement?
A total of 87,811,110 Offer Shares were successfully allocated, raising approximately NOK 158 million.
Who were the key investors in this placement?
Notable investors included Guy Urquhart, GCI Hofseth LLC, and Hofseth International AS, who pre-committed to significant share allocations.
What is the share price for the newly issued shares?
The fixed price for the newly issued shares during the private placement was set at NOK 1.80 per share.
What mechanisms are in place for future shareholder offerings?
The company plans to execute a subsequent offering allowing existing shareholders to purchase up to 16,666,666 new shares at the same price as the private placement. This is aimed at including those who could not participate in the initial placement.
